Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| See historical SUPN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Nov 16 | Outside Day | Range Expansion | 0.00% |
| Nov 15 | Doji - Bullish? | Reversal | 1.90% |
| Nov 13 | Calm After Storm | Range Contraction | -2.62% |
| Nov 12 | Calm After Storm | Range Contraction | -1.72% |
| Nov 9 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.96% |
| Nov 9 | Calm After Storm | Range Contraction | -2.96% |
| Nov 9 | Narrow Range Bar | Range Contraction | -2.96% |
| Nov 9 | NR7 | Range Contraction | -2.96% |
| Nov 9 | Inside Day | Range Contraction | -2.96% |
| Nov 8 | Spinning Top | Other | -3.58% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-06
- Sector: Healthcare
- Industry: Specialty & Advanced Pharmaceuticals
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more SUPN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 61.25 |
| 52 Week Low | 34.9 |
| Average Volume | 566,613 |
| 200-Day Moving Average | 48.1287 |
| 50-Day Moving Average | 47.2158 |
| 20-Day Moving Average | 45.5635 |
| 10-Day Moving Average | 43.928 |
| Average True Range | 2.061 |
| ADX | 17.52 |
| +DI | 16.6727 |
| -DI | 27.2797 |
| Chandelier Exit (Long, 3 ATRs ) | 43.287 |
| Chandelier Exit (Short, 3 ATRs ) | 45.853 |
| Upper Bollinger Band | 49.5109 |
| Lower Bollinger Band | 41.6161 |
| Percent B (%b) | 0.29 |
| BandWidth | 17.327027 |
| MACD Line | -1.0236 |
| MACD Signal Line | -0.8682 |
| MACD Histogram | -0.1555 |
| Fundamentals | Value |
|---|---|
| Market Cap | 2.23 Billion |
| Num Shares | 50.7 Million |
| EPS | 1.98 |
| Price-to-Earnings (P/E) Ratio | 22.19 |
| Price-to-Sales | 8.00 |
| Price-to-Book | 8.81 |
| PEG Ratio | 1.42 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 46.77 | ||||
| Resistance 3 (R3) | 46.48 | 45.26 | 46.29 | ||
| Resistance 2 (R2) | 45.26 | 44.53 | 45.40 | 46.13 | |
| Resistance 1 (R1) | 44.59 | 44.09 | 44.93 | 44.88 | 45.98 |
| Pivot Point | 43.37 | 43.37 | 43.53 | 43.51 | 43.37 |
| Support 1 (S1) | 42.70 | 42.64 | 43.04 | 42.99 | 41.88 |
| Support 2 (S2) | 41.48 | 42.20 | 41.62 | 41.73 | |
| Support 3 (S3) | 40.81 | 41.48 | 41.57 | ||
| Support 4 (S4) | 41.10 |
